We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Study Describes Use of Malaria Parasite Protein to Collect CTCs

By LabMedica International staff writers
Posted on 30 Aug 2018
A novel technique uses the malaria parasite protein VAR2CSA to bind circulating tumor cells (CTCs) from a wide variety of cancer types for collection and analysis.

VAR2CSA (Variant Surface antigen 2-CSA), which binds specifically to the cancer cell membrane carbohydrate oncofetal chondroitin sulfate (ofCS), belongs to the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family.

Isolation of metastatic CTCs from cancer patients is of high value for disease monitoring and molecular characterization. More...
Despite the development of many new CTC isolation platforms in the last decade, their isolation and detection has remained a challenge due to the lack of specific and sensitive markers.

In a feasibility study published in the August 16, 2018, online edition of the journal Nature Communications, investigators at the University of Copenhagen Faculty of Health and Medical Sciences (Denmark) presented a method for CTC isolation based on the specific binding of the malaria VAR2CSA protein to the tumor marker ofCS.

The investigators reported that VAR2CSA captured CTCs efficiently from hepatic, lung, pancreatic, and prostate cancer patients with minimal contamination of peripheral blood mononuclear cells. Furthermore, in 25 stage I–IV prostate cancer patient samples, CTC enumeration significantly correlated with disease stage.

"We have developed a method where we take a blood sample and with great sensitivity and specificity, we are able to retrieve the individual cancer cells from the blood. We catch the cancer cells in greater numbers than existing methods, which offers the opportunity to detect cancer earlier and thus improve outcome. You can use this method to diagnose broadly, as it is not dependent on cancer type. We have already detected various types of cancer cells in blood samples. And if there is a cancer cell in your blood, you have a tumor somewhere in your body," said senior author Dr. Ali Salanti, professor of immunology and microbiology at the University of Copenhagen Faculty of Health and Medical Sciences.

"Today, it is difficult to determine which stage cancer is at. Our method has enabled us to detect cancer at stages one, two, three and four. Based on the number of circulating tumor cells we find in someone's blood, we will be able to determine whether it is a relatively aggressive cancer or not so then to adjust the treatment accordingly," said Dr. Salanti.

Related Links:
University of Copenhagen Faculty of Health and Medical Sciences


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.